ARTICLE | Company News
Catalytica, Nabi deal
June 21, 1999 7:00 AM UTC
NABI acquired exclusive U.S. distribution rights to Aloprim intravenous allopurinol to control elevated uric acid levels in patients with leukemia, lymphoma and solid tumors. NABI, which will launch ...